# Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

> **NCT04566653** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 147 (actual)

## Conditions studied

- Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure

## Interventions

- **DRUG:** Calcium Polystyrene Sulphonate 15g/60 mL water
- **DRUG:** Lokelma® 5 g/45mL water
- **DRUG:** Lokelma® 10 g/45 mL water
- **DRUG:** Veltassa® 8,4 g/80mL water
- **DRUG:** Sodium Polystyrene Sulphonate 15g/60 mL water

## Key facts

- **NCT ID:** NCT04566653
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-23
- **Primary completion:** 2022-01-12
- **Final completion:** 2022-01-12
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566653, "Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04566653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*